Dopaminergic Loss and Pain in Parkinson's Disease

Pain Clinical Trial

Official title:

Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00940914
• Other study ID #: 0730302
• Secondary ID: AOL 2007
• Status: Completed
• Phase: Phase 2
• Start date: March 2009
• Est. completion date: July 2010

Study information

• Verified date: July 2020
• Source: University Hospital, Toulouse
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

About 46% of patients suffering from Parkinson's disease present pain disorders. Parkinson disease is characterized by loss of dopaminergic neurons. The aim of this study is to assess the relationship between the loss of dopaminergic neurons and the existence of pain in Parkinson's disease. Using single photon emission computerized tomography (SPECT) imaging (123I FP-CIT, which binds dopamine transporter) and the determination of subjective pain threshold, the investigators will establish correlations between dopaminergic degeneration and pain perception.

Description:

Parkinson's disease is a frequent neurodegenerative disease leading to motor handicap, cognitive and pain disorders. These pain disorders could be correlated to dopaminergic loss.

The clinical trial will be conducted in a single center (Neurology Department, Purpan Hospital, Toulouse, France). The study is classified as a physiopathology one. Twenty patients with Parkinson's disease, presenting pain disorders or not, will be selected. This clinical trial will last one year. All the exams, including image acquisition will be done the same day. These will take about 6 hours for each patient.

Expected results: Binding of 123I FP-CIT to dopamine transporters should negatively correlate with pain intensity and also with thermal pain thresholds in patients suffering from Parkinson's disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: July 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with clinically established Parkinson's disease according to the UKPDSBB (UK Parkinson's Disease Society Brain Bank) (Gibb et Less, 1998; Hugues et al, 1992).

• Male or Female patients, aged from 30 to 70 years.

• Patients must benefit from the French Social security system.

• Patients must give a written informed consent.

• Female fertile patients must use an efficient method of contraception.

If patients suffer from chronic pain, pain must be related to Parkinson's disease.

Exclusion Criteria:

• Patients with a syndrome other than the idiopathic Parkinson's disease.

• Patients suffering from important trembling during the OFF periods or abnormal involuntary movements (dyskinesia) during the ON periods, not allowing the imagery exam to be performed.

• Patients suffering from another disease causing chronic pain.

• Patients suffering from cancer.

• Patients with cognitive dysfunction.

• Patients not able to complete the scales.

• Pregnant, breastfeeding or fertile female patients not using an efficient method of contraception.

• Patients not willing to participle in the trial.

Related Conditions & MeSH terms

• Pain
• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• ioflupane 123I (DATSCAN®)
One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)

Locations

Country	Name	City	State
France	University Hospital Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

References & Publications (1)

Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, Kas A, Salabert AS, Ory-Magne F, Payoux P, Brefel-Courbon C. Dopaminergic denervation using [(123)I]-FPCIT and pain in Parkinson's disease: a correlation study. J Neural Transm (Vienna). 20 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Single photon emission computerized tomography (SPECT) will be used to evaluate binding of 123I FP-CIT to dopamine transporters. This exam will allow calculation of the ratio of specific to non specific binding of 123I FP-CIT to dopamine transporters.		Image acquisition (SPECT) will be performed after three hours post-injection of 123I FP-CIT.
Primary	Pain perception will be evaluated by the determination of subjective pain thresholds (thermal pain thresholds, thermotest). A thermode will be used to determine the heat and cold pain thresholds.		Image acquisition (SPECT) will be performed after three hours post-injection of 123I FP-CIT.
Secondary	Severity of Parkinson's disease will be evaluated with the Unified Parkinson's disease Rating Scale (UPDRS) and the Hoehn and Yahr scale		Evaluation will be done within three hours before image acquisition (SPECT).
Secondary	Short French version of McGill pain questionnaire (MPQ).		Evaluation will be done within three hours before image acquisition (SPECT).
Secondary	Pain intensity will be assessed using a 10 cm visual analogue scale (VAS) (0 = no pain; 10 = worst possible pain).		Evaluation will be done within three hours before image acquisition (SPECT).
Secondary	DN4 scale		Evaluation will be done within three hours before image acquisition (SPECT).
Secondary	Brief Inventory Pain		Evaluation will be done within three hours before image acquisition (SPECT).
Secondary	Hospital Anxiety and Depression (HAD) scale		Evaluation will be done within three hours before image acquisition (SPECT).